You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The paper, which is not peer-reviewed, said that use of the test as a first-step screening tool would require confirmation of more than 80 percent of its results.
Only 2.5 percent of Americans have been tested for COVID-19, even as industry scrambles to increase testing capacity and a second wave of cases may hit in the fall.
Danaher President and CEO Thomas Joyce will retire in September and will be replaced by Rainer Blair, the current executive VP of the life sciences division.
Abbott's RealTime CT/NG assay is currently only cleared by the US Food and Drug Administration for use with urogenital samples.
The new rate applies to clinical diagnostic lab tests using high-throughput technologies that can process more than 200 specimens per day.
Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.
Cepheid's Xpert Xpress SARS-CoV-2 rapid molecular diagnostic test can be used in high- and moderate-complexity labs and at the point of care in certain settings.
The deal is part of a wider collaboration between the companies to develop molecular diagnostic tests using their respective platforms.
A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.